The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative—Experiences from engaging with pharmaceutical policy makers
Introduction
Governments are struggling with providing their citizens with safe, effective and high quality medicines and, at the same time, ensuring best value for money and financial sustainability. Given the demographic developments such as aging populations, the launch of new medicines being granted high prices and stricter clinical targets [1], this challenge remains for European countries [2], [3], [4]. Policy makers have to take decisions on medicine prices and reimbursement, they need to select the most appropriate policy mix from a range of supply-side and demand-side measures, and they are recommended to promote a more rational use of medicines [5], [6], [7], [8], [9]. They need to constantly adjust their pharmaceutical policies in response to changes in the environment. Thus, information on pharmaceutical systems in other countries, particularly of the same region, and on the experiences made with specific policies elsewhere is vital for policy makers.
In the first years of this century the body of information about pharmaceutical policies in European countries was limited. A few studies were available, mainly produced by supranational institutions [10], [11], [12] and research institutions [13], [14], [15]. Contacts existed on a bilateral basis between international institutions and researchers on the one hand and public authorities in European countries on the other hand, but there were limited contacts among colleagues of Medicines Agencies or of ministries responsible for setting medicine prices or deciding on reimbursement in different countries. Having identified this urgent need for cross-country learning among policy makers, we decided to establish a network of competent authorities for pharmaceutical pricing and reimbursement. In 2004 we, organised in a consortium of an Austrian research institute and WHO, proposed a 2-year project called ‘Pharmaceutical Pricing and Reimbursement Information (PPRI)’ to the European Commission which agreed to co-fund it. The initiative is on-going though the organizational and funding framework has been modified over the years.
The objective of this paper is to present the Pharmaceutical Pricing and Reimbursement Information (PPRI) project as an illustrative example of an engagement with policy makers in the field of pharmaceutical pricing and reimbursement. We will discuss how the PPRI project evolved, how the organisational and funding framework was modified over the years and how these changes impacted the working methods and deliverables. Particularly, we will look into how the needs, particularly information needs, of the policy makers involved have changed following successful opportunities for cross-country learning. Finally, we will explore, on the example of PPRI, supportive and limiting factors of such an initiative, including challenges for sustainability, in order to allow similar undertakings to learn from these experiences.
Section snippets
Methods
The presentation of the Pharmaceutical Pricing and Reimbursement Information (PPRI) project and its changes over time is based on factual background information to set the scene, along with an assessment of the engagement with policy makers. For the analysis we draw from observations made by the authors, feedback provided by the involved policy makers at regular intervals during reflection rounds on the added value and sustainability of the initiative, and two external reports. The latter
From an European Commission co-funded project to a self-sustainable initiative
The Pharmaceutical Pricing and Reimbursement Information (PPRI) project started in April 2005, with the aim to develop a network of competent authorities to improve information and knowledge on the pharmaceutical systems in Europe and to facilitate cross-country learning among policy makers since no such initiative existed at that time. It was commissioned under the Public Health Information Programme of the European Commission (EC), Health and Consumer Protection Directorate-General and
Discussion
This paper describes the Pharmaceutical Pricing and Reimbursement Information (PPRI) network as an example for an engagement with policy makers, and presents its activities from its beginning in 2005 until today.
The PPRI initiative changed over the years, and the information needs of the involved policy makers also changed. One might argue that this is the result of successful capacity building activities in the early stages of PPRI when, due to limited information in the public domain, the
Conclusions
The engagement with the policy makers in the PPRI network has proved to be a long-term cooperation, in spite of limitations in funding. The sustainability of the network has been ensured up to now by the contributions of the policy makers involved: Seeing a personal added value for their daily work, they are committed to getting involved and contributing time resources, ideas and data.
The major principles of PPRI are trust and mutual respect among the network members, a common understanding of
Ethical approval
Not declared.
Funding
No specific funding was provided for writing the article.
No writing assistance was utilized in the production of this manuscript.
Competing interests
None declared.
Acknowledgements
We deeply thank the policy makers involved the PPRI (Pharmaceutical Pricing and Reimbursement Information) network for their active participation and their willingness to share data and experiences. Their commitment has contributed to the success and sustainability of the PPRI. It is the policy of PPRI not to disclose the names of the policy makers, but their affiliated institutions were referred to in the article.
Furthermore, we are grateful to (former) colleagues of the Austrian Health
References (44)
- et al.
Personalised medicine as a challenge for public pricing and reimbursement authorities—a survey among 27 European countries on the example of trastuzumab
Health Policy
(2013) - et al.
The open nature of innovation in the hospital sector: the role of external collaboration networks
Health Policy Technol
(2012) - et al.
Enhancing the rational use of new medicines across European health care systems
Eur J Clin Pharmacol
(2008) - Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Brussels:...
- Espin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Brussels:...
- et al.
Priority medicines for Europe and the world. 2013 Update
(2013) - World Health Organization (WHO). How to develop and implement a national drug policy, 2nd ed. Geneva; 2001....
- World Health Organisation. Measuring medicine prices, availability, affordability and price components. Geneva: WHO,...
- OECD. Pharmaceutical Pricing Policies in a Global Market. Paris: OECD, 2008....
- World Health Organization (WHO). Promoting rational use of medicines: Core components. WHO Policy Perspectives on...